Acura Pharmaceuticals Inc (ACUR.O)
20 Dec 2013
|Market Cap (Mil.):||$76.83|
|Shares Outstanding (Mil.):||48.32|
NEW YORK, Dec 9 - Acura Pharmaceuticals Inc : * Pharma up 12.4 percent to $1.90 premarket; says FDA to review data from failed painkiller trial
- Acura Pharmaceuticals Inc said the U.S. Food and Drug Administration agreed to review the results of a failed mid-stage trial of a painkiller made with the company's technology designed to deter abuse.
Dec 9 - Acura Pharmaceuticals Inc said the U.S. Food and Drug Administration agreed to review the results of a failed mid-stage trial of a painkiller made with the company's technology designed to deter abuse.
- Acura Pharmaceuticals Inc said a painkiller made with its abuse-deterrent technology did not show statistically significant results in reducing likability among abusers, sending its shares down as much as 34 percent in extended trading.
(Adds details, background, analyst comment; updates share movement)
|Pain Therapeutics, Inc. (PTIE.OQ)||$4.39||+0.32|
|Pfizer Inc. (PFE.N)||$30.25||-0.46|
|Grifols SA (GRLS.MC)||€33.72||-0.45|
|Grifols SA (GRLSbn.MC)||€25.90||+0.20|
|Onyx Pharmaceuticals, Inc. (ONXX.OQ)||--||--|
|AstraZeneca plc (AZN.L)||3,588.50p||-10.50|
|Bayer AG (BAYGn.DE)||€99.46||+0.06|
|Bayer AG (BAYE.F)||--||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Acura Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.